A new platform aimed at streamlining clinical trials in order to lower costs – and increase the efficiency and success rate of a drug or the development of a medical device – has been unveiled by Ben-Gurion University of the Negev (BGU).
The yet-to-be-named programme reportedly “leverages machine learning to optimise a clinical trial’s chances of success” through the analysis of factors including...
Back in April, Borderlands 3 – a big budget, role-playing first-person shooter videogame that sold over 8 million copies within six months of its release – received a free update that introduced a new mini-game to its players.
Taking the form of a retro-style arcade cabinet in the home base's medical bay, "Borderlands Science" has players shifting colored blocks between rows and columns to solve...
Novartis's digital strategy hasn't changed too much since MobiHealthNews spoke with the pharma company in 2018. But, at the HLTH virtual conference this week, Novartis Chief Digital Officer Betrand Bodson reiterated the company's four-part strategy, focusing especially on its partnerships, including those with Microsoft, Amazon and China's Tencent.
"We started this agenda in earnest two and a...
The year 2020 will go down in history as one of the most challenging of our lifetime. Thinking back to January, none of us would have predicted the emergence of a pandemic-causing virus, let alone its devastating outcomes that have affected tens of millions of lives around the world so far. It has changed the way we do business, conduct events, and of course, report the news.
Closer to home, we’...
Abbott announced that its Libre Sense Glucose Sport Biosensor has achieved a CE Mark, paving the way for a European roll-out.
The Libre Sense biosensor provides continuous glucose monitoring (CGM) to help athletes understand the efficacy of their nutrition choices on training and competition.
Based on Abbott's FreeStyle Libre technology for people living with diabetes, it is the first personal-...
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...
It’s no secret that digital is shaping what clinical trials will look like in the future. A recently published position paper published in Nature discusses the potentials and challenges of digital clinical trials. The paper builds on a workshop held by the U.S. National Institutes of Health and the National Science Foundation in April of 2019.
One of the big opportunities that the paper outlines...
Real-world evidence (RWE) technology startup Aetion has extended last year's $63 million Series B with a new $19 million raise. The funds come as strategic investments from Johnson & Johnson Innovation, JJDC, EDBI and Greenspring Associates, all three of which are new supporters of the company.
WHAT IT DOES
Founded in 2013, the company's platform provides insights from RWE to decision-makers...
The Consumer Technology Association (CTA) announced this morning a new group of 24 technology and digital health companies aiming to develop industry-wide standards for digital therapeutics use.
Headlined by big names like Google Health, Doctor on Demand, HP, Livongo and ResMed (see below for the full list), the initiative is tackling the amorphous definitions and terminologies that abound within...
Today One Drop announced a string of new deals with Bayer that could bring the digital diabetes-management company nearly $100 million in new funds.
The agreements include the closure of a Series C financing round led by the pharma giant, as well as $64 million in unspecified development commitments and potential commercial milestone payments.
Launched in late 2016, One Drop's wireless blood...
